Lipidica, a.s.

At Lipidica, we are committed to transforming the landscape of cancer detection to enhance early diagnosis. Our mission is clear: to conduct a rigorous clinical performance study according to IVDR (In Vitro Diagnostic Medical Device Regulation) and in close collaboration with clinicians, targeting individuals with hereditary/familial risk factors and validate the clinical efficacy of our LDPC lipidomic test, a breakthrough innovation in the early detection of pancreatic cancer. We are dedicated to advancing healthcare by providing clinicians with a powerful tool to identify this deadly disease at its earliest, most treatable stages. Lipidica, a.s. was established in 2022 as a spin-off company of the University of Pardubice and the investment partner FONS JK Group a.s., based on the technology developed by the Mass Spectrometry Group of Prof. Michal Holcapek.